Effect of timing of casirivimab and imdevimab administration relative to mRNA-1273 COVID-19 vaccination on vaccine-induced SARS-CoV-2 neutralising antibody responses: a prospective, open-label, phase 2, randomised controlled trial

Effect of timing of casirivimab and imdevimab administration relative to mRNA-1273 COVID-19 vaccination on vaccine-induced SARS-CoV-2 neutralising antibody responses: a prospective, open-label, phase 2, randomised controlled trial

Deeper insight is needed on how monoclonal antibodies (mAbs) affect vaccine-mediated immune responses when targeting the same protein. We describe the first prospective randomised trial designed to understand mAb-mediated alterations in vaccine-induced immune responses to SARS-CoV-2 spike protein ep...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The Lancet infectious diseases 2024-09
Hauptverfasser: Isa, Flonza, Gonzalez Ortiz, Ana M, Meyer, Jonathan, Hamilton, Jennifer D, Olenchock, Benjamin A, Brackin, Taylor, Ganguly, Samit, Forleo-Neto, Eduardo, Faria, Lori, Heirman, Ingeborg, Marovich, Mary, Hutter, Julia, Polakowski, Laura, Irvin, Susan C, Thakur, Mazhar, Hooper, Andrea T, Baum, Alina, Petro, Christopher D, Fakih, Faisal A, McElrath, M Juliana, De Rosa, Stephen C, Cohen, Kristen W, Williams, LaTonya D, Hellman, Caleb A, Odeh, Ahmad J, Patel, Aloki H, Tomaras, Georgia D, Geba, Gregory P, Kyratsous, Christos A, Musser, Bret, Yancopoulos, George D, Herman, Gary A, Turner, Kenneth C, Kim, Yunji, Konis, George, Rosenthal, Mark J, Trbovic, Caryn F, Kowal, Bari, DiCioccio, A Thomas, Dakin, Paula
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Deeper insight is needed on how monoclonal antibodies (mAbs) affect vaccine-mediated immune responses when targeting the same protein. We describe the first prospective randomised trial designed to understand mAb-mediated alterations in vaccine-induced immune responses to SARS-CoV-2 spike protein epitopes. This randomised, open-label, parallel-group study assessed the potential interaction of a mAb combination, casirivimab and imdevimab, with a vaccine, Moderna's mRNA-1273, in healthy SARS-CoV-2 immunologically naive, seronegative adults at six centres in the USA. Participants were randomly assigned (per prespecified randomisation ratios within enrolment waves) according to a computer-generated randomisation scheme, stratified by age (
ISSN:1473-3099
1474-4457
1474-4457
DOI:10.1016/S1473-3099(24)00421-3